Cargando…

Plerixafor use in autologous hematopoietic stem cell mobilization: Experience from a single center in Southern India

BACKGROUND: Plerixafor is used for patients at risk of Stem cell mobilization failure based on clinical factors or low peripheral blood CD34 count. It is also added upfront to any mobilization irrespective of risk factor, but the cost-effectiveness of the approach is an issue. Data on plerixafor in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Das, Soumya, Kayal, Smita, Dubashi, Biswajit, Basavarajegowda, Abhishekh, Pasupala, Nanda Kishore, Kulkarni, Rajendra, Dhanraju, Krishnappa, Pani, Chinmaya Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528564/ https://www.ncbi.nlm.nih.gov/pubmed/36199417 http://dx.doi.org/10.4103/ajts.ajts_106_21

Ejemplares similares

Late Effects of Breast Cancer Treatment and Outcome after Corrective Interventions
por: Pillai, Unni S, et al.
Publicado: (2019)

Prevalence of C, c, E, e, K, and k antigens in RhD-negative blood donors in and around Puducherry
por: Gopal, Sridhar, et al.
Publicado: (2022)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Seroprevalence of cytomegalovirus among blood donors at a tertiary care hospital in Puducherry, India. Is testing donated blood for cytomegalovirus a viable option?
por: Cherukat, Jayasree, et al.
Publicado: (2021)

Deciphering a delayed hemolytic transfusion reactions nightmare – Case of Chido/Roger antibodies
por: Das, Soumya, et al.
Publicado: (2019)

Baricitinib: Two Birds with One Stone
por: Saj, Fen, et al.
Publicado: (2022)

Prevalence of dengue NS1 antigenemia among healthy blood donors in a tertiary care hospital in Southern India
por: Remakanth, Remi, et al.
Publicado: (2021)

Plerixafor
por: Slater, Susan
Publicado: (2012)

Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers
por: Visram, Alissa, et al.
Publicado: (2018)

Level of Anxiety and Depression and Its Clinical and Sociodemographic Determinants among the Parents of Children with Cancer Undergoing Chemotherapy
por: Srivastava, Shivayan, et al.
Publicado: (2020)

Assessment of iron status in regular blood donors in a tertiary care hospital in Southern India
por: Anju, Joy, et al.
Publicado: (2022)

Transfusion reactions in neonates and pediatrics: How and why are they different?
por: Basavarajegowda, Abhishekh, et al.
Publicado: (2023)

Poster: ABCL-334: Impact of COVID-19 Pandemic on Treatment Duration in Curable Cancers: Comparison of Patients with DLBCL Treated Before and During: A Retrospective Record-Based Study
por: Anandaradje, Annuja, et al.
Publicado: (2021)

ABCL-334: Impact of COVID-19 Pandemic on Treatment Duration in Curable Cancers: Comparison of Patients with DLBCL Treated Before and During: A Retrospective Record-Based Study
por: Anandaradje, Annuja, et al.
Publicado: (2021)

Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study
por: Saj, Fen, et al.
Publicado: (2023)

P909: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE CHEMOTHERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: POMACE PHASE II STUDY
por: Saj, Fen, et al.
Publicado: (2023)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021)

Cytotoxic chemotherapy is associated with decreased bone mineral density in postmenopausal women with early and locally advanced breast cancer
por: Nisha, Yadav, et al.
Publicado: (2023)

Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: A systematic review and meta-analysis
por: Yang, Xiaoyang, et al.
Publicado: (2019)

P1378: PLERIXAFOR AND GRANULOCYTE COLONY STIMULATING FACTOR FOR POOR MOBILIZERS IN PATIENTS UNDERGOING AUTOLOGOUS PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE INSTITUTION STUDY
por: El Cheikh, J., et al.
Publicado: (2022)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

Herniation of blood bag during component preparation
por: Gnanaraj, John, et al.
Publicado: (2023)

Clinical significant anti-P1 antibody with wide thermal amplitude: A tale of successful blood management
por: Thulasiram, Nallagondla, et al.
Publicado: (2023)

Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells
por: Kuang, Pu, et al.
Publicado: (2022)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update [Corrigendum]
Publicado: (2022)

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
por: Shumilov, Evgenyi, et al.
Publicado: (2019)

Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC)
por: Morland, Bruce, et al.
Publicado: (2020)

Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis
por: Parody, Rocío, et al.
Publicado: (2020)

Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
por: Agarwal, Rishi, et al.
Publicado: (2012)

Successful “on‐demand” plerixafor for autologous peripheral blood stem‐cells transplantation for relapsed/refractory germ cell tumors
por: Corbingi, Andrea, et al.
Publicado: (2021)

Assessment of Oral Anticancer Medication Adherence: A Survey from a Tertiary Cancer Center
por: Ramachandiran, Balaji, et al.
Publicado: (2021)

Perioperative normovolemic hemodilution in a case of leiomyomatous erythrocytosis
por: Rafi, Aboobacker Mohamed, et al.
Publicado: (2014)

Feasibility of high-yield plateletpheresis in routine practice: Experience from tertiary health center from South India
por: Sahoo, Dibyajyoti, et al.
Publicado: (2023)

Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary Care Institute in Southern India
por: Sylvia, Mary Theresa, et al.
Publicado: (2016)

Challenges in the Management of Lung Cancer: Real-World Experience from a Tertiary Center in South India
por: Gopal, Vishnu, et al.
Publicado: (2021)

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization
por: Jørgensen, Astrid S., et al.
Publicado: (2021)

Management of Bombay Rh negative with clinically significant anti-S for CABG surgery
por: Anuragaa, S., et al.
Publicado: (2022)

The “collateral damage” of the war on COVID-19: impact of the pandemic on the care of epithelial ovarian cancer
por: Goenka, Luxitaa, et al.
Publicado: (2021)

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
por: Karpova, D, et al.
Publicado: (2013)

A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19
por: Umakanthan, Srikanth, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_peub0q1na4i6kou286srf5mdfd